PitchBook-新兴空间简报_长寿技术（英）-2025_8页_569kb

Longevity Technology Summary

Longevity tech refers to companies developing restorative treatments to combat aging and extend lifespan by targeting fundamental biological mechanisms, such as genomic instability and cellular senescence. Historically, it focused on age-related diseases but has shifted to prevention due to advances in epigenetics and cellular reprogramming.

Key technologies include epigenetic reprogramming, which rejuvenates cells by altering epigenetic marks, and senolytics, which eliminate senescent cells. Applications span neurodegeneration, cardiovascular health, cancer prevention, and immune system rejuvenation, potentially improving multiple age-related conditions systemically.

Despite VC investments totaling billions, with leaders like Altos Labs and Unity Biotechnology, challenges persist: scientific complexity, regulatory hurdles (as aging isn't classified as a disease), and commercial uncertainties hinder market entry. Recent deals indicate investor confidence, but public trust and payor acceptance remain barriers.

The market grows as the global population ages, with potential to evolve like oncology. Clinical validation and regulatory innovation are crucial for longevity biotech to deliver transformative therapies.

• Major Areas: Epigenetic reprogramming and senolytics are prominent technologies.
• Investment: Fluctuations in funding (e.g., $294M in 2024), backed by billionaires and specialized funds.
• Limitations: No approved therapies yet; scientific risks, regulatory issues, and ethical concerns limit widespread adoption.